About MaaT Pharma
MaaT Pharma is a company based in Lyon (France) founded in 2014.. MaaT Pharma has raised $42.3 million across 14 funding rounds from investors including Bpifrance, European Union and Symbiosis. MaaT Pharma offers products and services including MaaT013, MET-N, MET-C, gutPrint®, and MaaT033. MaaT Pharma operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Lyon, France
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Maat Pharma
-
Annual Revenue
$3.35 M (USD)44.34as on Dec 31, 2024
-
Net Profit
$-30.02 M (USD)-46.59as on Dec 31, 2024
-
EBITDA
$-31.76 M (USD)-28.76as on Dec 31, 2024
-
Total Equity Funding
$42.3 M (USD)
in 14 rounds
-
Latest Funding Round
$2.24 M (USD), Grant
Jul 20, 2021
-
Investors
Bpifrance
& 10 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of MaaT Pharma
MaaT Pharma is a publicly listed company on the EURONEXT with ticker symbol MAAT in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of MaaT Pharma
MaaT Pharma offers a comprehensive portfolio of products and services, including MaaT013, MET-N, MET-C, gutPrint®, and MaaT033. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Phase 3 therapy for improving cancer patient survival rates.
Microbiome ecosystem treatment for oncology applications.
Gut-focused therapy for cancer-related immune modulation.
Platform for analyzing microbiome in cancer contexts.
Phase 2b treatment for patients undergoing allo-HSCT.
Funding Insights of MaaT Pharma
MaaT Pharma has successfully raised a total of $42.3M across 14 strategic funding rounds. The most recent funding activity was a Grant round of $2.24 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 14
- Last Round Grant — $2.2M
-
First Round
First Round
(01 Dec 2014)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Grant - MaaT Pharma | Valuation |
investors |
|
| Dec, 2020 | Amount | Series B - MaaT Pharma | Valuation | Bpifrance | |
| Sep, 2020 | Amount | Grant - MaaT Pharma | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in MaaT Pharma
MaaT Pharma has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Bpifrance, European Union and Symbiosis. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are directed toward life science sectors.
|
Founded Year | Domain | Location | |
|
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US
|
Founded Year | Domain | Location | |
|
Growth and acquisition investments are managed by Credit Mutuel Equity.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by MaaT Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - MaaT Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Maat Pharma Comparisons
Competitors of MaaT Pharma
MaaT Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Biosolutions and enzymes are developed for biotechnology applications across industries.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Maat Pharma
Frequently Asked Questions about MaaT Pharma
When was MaaT Pharma founded?
MaaT Pharma was founded in 2014.
Where is MaaT Pharma located?
MaaT Pharma is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
Is MaaT Pharma a funded company?
MaaT Pharma is a funded company, having raised a total of $42.3M across 14 funding rounds to date. The company's 1st funding round was a Grant of $147K, raised on Dec 01, 2014.
What is the annual revenue of MaaT Pharma?
Annual revenue of MaaT Pharma is $3.35M as on Dec 31, 2024.
What does MaaT Pharma do?
MaaT Pharma was established in 2014 in Lyon, France, within the biotech sector. Microbiome-based treatments are created for addressing intestinal dysbiosis in patients with malignant blood diseases or bone infections. Autologous intestinal microbiota transplants are employed as the primary method. Heavy therapies that induce dysbiosis are countered through these interventions. Operations center on therapeutic development for such conditions, with a focus on clinical applications.
Who are the top competitors of MaaT Pharma?
MaaT Pharma's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does MaaT Pharma offer?
MaaT Pharma offers MaaT013, MET-N, MET-C, gutPrint®, and MaaT033.
Is MaaT Pharma publicly traded?
Yes, MaaT Pharma is publicly traded on EURONEXT under the ticker symbol MAAT.
Who are MaaT Pharma's investors?
MaaT Pharma has 11 investors. Key investors include Bpifrance, European Union, Symbiosis, Celeste Management, and Skyviews Life Science.
What is MaaT Pharma's ticker symbol?
The ticker symbol of MaaT Pharma is MAAT on EURONEXT.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.